Antibody drug conjugates, or ADCs, are still holding on to their spot as one of the hottest areas in cancer care—and AbbVie, ...

Currently, Alphamab trades at a price-to-earnings (P/E) ratio of 44 times, even higher than the 30 times for Henlius Biotech ...

Pfizer’s 7%+ yield is tempting, but rising political, regulatory, and business risks threaten its stability and growth ...

Researchers at Araris Biotech AG have developed antibody-drug conjugate (ADC) technology that allows single-step connection of antibody to drug via a novel RKAA peptide linker that stably prevents the ...

Erika Hamilton, MD, discusses the mechanism of action of emiltatug ledadotin, a B7-H4-directed Dolasynthen antibody-drug conjugate.

The clearance ushers in a closely-watched launch for Gilead, which aims to show a long-acting injection can upend a market ...

The companies aim to generate preclinical proof-of-concept data on SRB123 and quickly take it into clinical trials.

In this video, Sonali M. Smith, MD, discusses several notable studies on new treatment combinations and other options for ...

Merck just kicked off its Phase 3 IDeate-Prostate01 trial, handing the first dose of ifinatamab deruxtecan to a patient ...

The company is also entitled to royalties from commercial sales from the three ADC programmes. Glykos CEO Juhani Saarinen ...